The North America Transfection Reagents and Equipment Market size was valued at USD 1,340.5 Million in 2025 and is expected to reach USD 4,025.8 Million by 2035, registering a CAGR of 10.5% from 2024 to 2035. The market is driven by increasing R&D in cell and gene therapy, technological advancements, and heightened demand for precision medicine. The competitive landscape features key industry participants like Thermo Fisher Scientific, Lonza, and Bio-Rad, who are introducing robust transfection solutions to support the evolving research environment.
The economic impact of tariffs on "North America Transfection Reagents and Equipment Market".
Market Growth Drivers
Expanding Adoption of Cell & Gene Therapy: The rising prevalence of genetic disorders and chronic diseases is fueling the demand for cell and gene therapy research. Major players like Thermo Fisher Scientific are enhancing their portfolio of transfection reagents and equipment to cater to evolving research requirements, contributing significantly to market growth. The availability of advanced electroporation systems and efficient lipid-based reagents is enabling rapid transfection even in hard-to-transfect cell lines, thus accelerating scientific discoveries in oncology and immunology.
Surge in Biotech and Pharmaceutical R&D Investments: Increased funding and partnerships between biotech companies, such as Lonza and Bio-Rad Laboratories, are propelling innovations in transfection technology. These investments are directed at optimizing gene expression protocols, improving transfection efficiency, and minimizing cytotoxicity. Consequently, pharmaceutical companies are leveraging cutting-edge transfection tools for target validation and drug discovery, leading to sustained market demand.
Market Trends
Integration of Automation in Transfection Workflows: Automation is playing a pivotal role in enhancing repeatability and throughput in transfection experiments. Companies like Agilent Technologies and Thermo Fisher Scientific have introduced automated liquid handling platforms that streamline transfection processes. These systems accommodate parallel sample processing, minimize manual intervention, and ensure consistency, which is especially valuable for large-scale screening applications in drug development and functional genomics.
Rising Utilization of CRISPR-based Gene Editing: The proliferation of CRISPR/Cas9 technology has significantly transformed the transfection landscape. Vendors are now developing specialized reagents and delivery systems tailored for CRISPR applications, such as Lipofectamine CRISPRMAX from Thermo Fisher Scientific. This trend is enhancing genome editing efficiency and specificity, supporting advancements in gene therapy and personalized medicine across North America.
Market Opportunity
Emergence of Non-viral Delivery Solutions: The growing preference for non-viral transfection methods presents lucrative opportunities, especially in clinical and therapeutic applications. Key vendors, including Polyplus-transfection, are actively developing non-viral reagents to address safety and scalability challenges, fostering adoption among academic and biopharmaceutical research communities.
Expansion into Personalized Medicine: The shift toward personalized medicine is creating new opportunities for tailored transfection solutions. Companies like Bio-Rad Laboratories are focusing on customizable reagent formulations to support precision gene modulation, paving the way for patient-specific therapies and driving future market expansion.
North America Transfection Reagents and Equipment Market Revenue (USD Million), 2020-2035
The chart demonstrates a steady upward trend in market revenue from 2020 to 2035. Starting at USD 650 million in 2020, the market experiences consistent year-on-year growth, reaching USD 1,340.5 million by 2025 and projected to achieve USD 4,025.8 million by 2035. This remarkable growth trajectory can be attributed to increasing investments in biomedical research, growing demand for gene-modulation technologies, and expanding clinical application of transfection solutions. The CAGR of 10.5% highlights robust market prospects, with the highest acceleration expected beyond 2028 due to emerging biotechnology trends and greater adoption of advanced equipment.
North America Transfection Reagents and Equipment Market by Region Share (%), 2025
The pie chart displays the market share by key North American regions for 2025. The United States leads substantially with a 73% share, supported by advanced healthcare infrastructure, extensive R&D activity, and the presence of leading manufacturers. Canada follows at 17%, leveraging investments in university research and biotech startups. Mexico captures 7% of the market, benefitting from rising pharmaceutical outsourcing. Other North American countries and the Caribbean account for the remaining 3%. The chart illustrates the strong dominance of the US, while signaling potential for growth in Canadian and Mexican markets driven by increasing biopharma collaboration and research funding.
Recent Developments in North America Transfection Reagents & Equipment Market
In January 2024, Thermo Fisher Scientific announced the expansion of its Gibco Cell Culture portfolio with the launch of new transfection reagents designed specifically for mRNA delivery. These reagents optimize transfection efficiency and cell viability, meeting growing demand in vaccine development and gene therapy research.
In February 2024, Lonza introduced the Nucleofector Platform 4.0, which features advanced electroporation technology for higher transfection yields and scalability. This next-generation equipment supports a broad range of cell types, including hard-to-transfect primary cells, enabling enhanced functionality in therapeutic and research applications.
In March 2024, Bio-Rad Laboratories completed the acquisition of Cellectricon, a Swedish company specializing in cell electroporation systems. This move is aimed at strengthening Bio-Rad’s transfection equipment lineup, expanding its application base in neuroscience and functional genomics research throughout North America.
Press Releases